Name: Cysteamine HCl
Brand: Selleck Chemicals
SKU: S4206
Availability: InStock
Rating: 5 (3 reviews)

Jump to

Quality Control

Batch: S420601 DMSO]23 mg/mL]false]Water]23 mg/mL]false]Ethanol]23 mg/mL]false Purity: 100.0%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS/MSDS
Datasheet

100.0

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism
Other Antioxidant Inhibitors	Elamipretide (SS-31, MTP-131) EGCG ((-)-Epigallocatechin Gallate) Tangeretin Silymarin Gipsoside (+)-Catechin Hydroxygenkwanin Rutin (trihydrate) Oleuropein (-)Epicatechin

Solubility

In vitro
Batch:

DMSO : 23 mg/mL (202.44 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 23 mg/mL

Ethanol : 23 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.15mg/ml (10.12mM)	Taking the 1 mL working solution as an example, add 50 μL of 23 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.16mg/ml (1.41mM)	Taking the 1 mL working solution as an example, add 50 μL of 3.2 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	113.61	Formula	C₂H₇NS.HCl	Storage (From the date of receipt)	3 years -20°C powder (seal)
CAS No.	156-57-0	Download SDF		Storage of Stock Solutions	Solutions are unstable. Prepare fresh or purchase small, pre-packaged sizes. Repackage upon receipt.
Synonyms	Mercaptamine			SMILES	C(CS)N.Cl

Read more about storage stability CAS number SMILES

Mechanism of Action

In vitro	Cysteamine HCl has been shown to increase intracellular glutathione levels in cystinotic cells, thus restoring the altered redox state of the cells. Also increased rates of apoptosis in cystinotic cells, which are thought to be the result of increased caspase 3 and protein kinase Cε activity, is counteracted by this compound administration. It has antioxidant properties as a result of increasing glutathione production. This chemical is an excellent scavenger of ^OH and HOCl; it also reacts with H₂O₂. This agent increases the production of several heat shock proteins (HSP), including the murine Hsp40. It exerts a dose-dependent effect on the doxorubicin-induced death of cancer cells, measured in both HeLa cells and B16 cells, whereas this compound treatment alone had no influence on cell survival. In addition, in a doxorubicin-resistant breast cancer cell line, the addition of this chemical to doxorubicin results in a dramatic increase in cell death. This compound (100 μM) significantly is able to increase the intracellular GSH levels and the percentage of embryos that developed to the blastocyst stage of culture matured oocytes.
In vivo	Cysteamine is introduced as a treatment for cystinosis by depleting lysosomal cystine. This compound can inhibit transglutaminase activity by binding to the cysteine in its active center. It increases brain levels of brain-derived neurotrophic factor (BDNF), which is caused by the increased expression of the heat shock DNAJ-containing protein 1 (HSJ1). This chemical inhibits the formation of gastric and mammary tumors that are induced chemically or after irradiation, respectively. The administration of this compound is also able to inhibit the metastasis of pancreatic cancer in a mouse model by decreasing the expression and activity of metalloproteinases.
References	[1] https://pubmed.ncbi.nlm.nih.gov/23416144/ [2] https://pubmed.ncbi.nlm.nih.gov/8607972/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-24)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06990984	NOT_YET_RECRUITING	Leigh Syndrome	Thiogenesis Therapeutics, Inc.	2026-10	PHASE2
NCT05994534	ACTIVE_NOT_RECRUITING	Cystinosis	Nacuity Pharmaceuticals, Inc.	2023-10-29	PHASE1; PHASE2
NCT02735707	RECRUITING	Community-acquired Pneumonia, Influenza, COVID-19	UMC Utrecht	2016-04-11	PHASE3
NCT07477288	COMPLETED	Skin Aging	Hasanuddin University	2025-03-12	PHASE2
NCT06278948	UNKNOWN	Melasma	Cosmetique Active International	2023-10-06
NCT05656833	UNKNOWN	Melasma	UnionDerm	2022-10-28

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Cysteamine HCl Antioxidant chemical

Chemical Structure

Molecular Weight: 113.61